TY - JOUR
T1 - The Emerging Drugs Network of Australia – Victoria Clinical Registry
T2 - A state-wide illicit substance surveillance and alert network
AU - Syrjanen, Rebekka
AU - Schumann, Jennifer
AU - Fitzgerald, John
AU - Gerostamoulos, Dimitri
AU - Abouchedid, Rachelle
AU - Rotella, Joe Anthony
AU - Knott, Jonathan
AU - Maplesden, Jacqueline
AU - Hollerer, Hans
AU - Hannon, Liam
AU - Bourke, Elyssia
AU - Hodgson, Sarah E.
AU - Greene, Shaun L.
N1 - Funding Information:
The Emerging Drugs Network of Australia – Victoria project site investigators: Professor Andis Graudins, Monash Health, Victoria, Australia; Dr Hweemin Lee, Monash Health, Victoria, Australia; Ms Angela Dean, Melbourne Health, Victoria, Australia; Dr Siba Sulaeman, Peninsula Health, Victoria, Australia. The Victorian Institute of Forensic Medicine: Mr Matthew Di Rago, Victorian Institute of Forensic Medicine, Victoria, Australia; Ms Samantha Joubert, Victorian Institute of Forensic Medicine, Victoria, Australia; Dr Jared Castle, Victorian Institute of Forensic Medicine, Victoria, Australia. The EDNAV project acknowledges funding provided by the Department of Health (Victorian State Government) and the Emerging Drugs Network of Australia (EDNA).
Publisher Copyright:
© 2022 Australasian College for Emergency Medicine.
PY - 2023/2
Y1 - 2023/2
N2 - Objectives: With an increasingly dynamic global illicit drug market, including the emergence of novel psychoactive substances, many jurisdictions have moved to establish toxicosurveillance systems to enable timely detection of harmful substances in the community. This paper describes the methodology for the Emerging Drugs Network of Australia – Victoria (EDNAV) project, a clinical registry focused on the collection of high-quality clinical and analytical data from ED presentations involving illicit drug intoxications. Drug intelligence collected from the project is utilised by local health authorities with the aim to identify patterns of drug use and emerging drugs of concern. Methods: The project involves 10 public hospital EDs in Victoria, Australia. Patients 16 years and over, presenting to a network ED with a suspected illicit drug-related toxicity and a requirement for venepuncture are eligible for inclusion in the study under a waiver of consent. Clinical and demographic parameters are documented by site-based clinicians and comprehensive toxicological analysis is conducted on patient blood samples via specialised forensic services. All data are then deidentified and compiled in a project specific database. Results: Cases are discussed in weekly multidisciplinary team meetings, with a view to identify potentially harmful substances circulating in the community. High-risk signals are escalated to key stakeholders to produce timely and proportionate public health alerts with a focus on harm minimisation. Conclusions: The EDNAV project represents the first centralised system providing near real-time monitoring of community drug use in Victoria and is fundamental in facilitating evidence-based public health intervention.
AB - Objectives: With an increasingly dynamic global illicit drug market, including the emergence of novel psychoactive substances, many jurisdictions have moved to establish toxicosurveillance systems to enable timely detection of harmful substances in the community. This paper describes the methodology for the Emerging Drugs Network of Australia – Victoria (EDNAV) project, a clinical registry focused on the collection of high-quality clinical and analytical data from ED presentations involving illicit drug intoxications. Drug intelligence collected from the project is utilised by local health authorities with the aim to identify patterns of drug use and emerging drugs of concern. Methods: The project involves 10 public hospital EDs in Victoria, Australia. Patients 16 years and over, presenting to a network ED with a suspected illicit drug-related toxicity and a requirement for venepuncture are eligible for inclusion in the study under a waiver of consent. Clinical and demographic parameters are documented by site-based clinicians and comprehensive toxicological analysis is conducted on patient blood samples via specialised forensic services. All data are then deidentified and compiled in a project specific database. Results: Cases are discussed in weekly multidisciplinary team meetings, with a view to identify potentially harmful substances circulating in the community. High-risk signals are escalated to key stakeholders to produce timely and proportionate public health alerts with a focus on harm minimisation. Conclusions: The EDNAV project represents the first centralised system providing near real-time monitoring of community drug use in Victoria and is fundamental in facilitating evidence-based public health intervention.
KW - early warning system
KW - illicit drugs
KW - novel psychoactive substances
KW - public health
KW - toxicosurveillance
UR - http://www.scopus.com/inward/record.url?scp=85137213711&partnerID=8YFLogxK
U2 - 10.1111/1742-6723.14059
DO - 10.1111/1742-6723.14059
M3 - Article
C2 - 36053993
AN - SCOPUS:85137213711
SN - 1742-6731
VL - 35
SP - 82
EP - 88
JO - EMA - Emergency Medicine Australasia
JF - EMA - Emergency Medicine Australasia
IS - 1
ER -